Biodexa Pharmaceuticals raised gross proceeds of $3.5 million on July 1 after reporting £3.23 million in cash and cash equivalents at June 30. The funding supports expanded clinical development and patient access activities, but forecasts indicate further financing will be required during Q4 2026, with potential dilution for investors.

Key Highlights

  • Serenta enrollment reached 92 subjects out of a planned 168 after the period ended.
  • The company had $26.08 million undrawn from its $35 million Equity Line of Credit at June 30.
  • Biodexa completed a financing transaction raising $3.5 million in gross proceeds on July 1, 2026.

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) reported £3.23 million in cash and cash equivalents at June 30, 2026, after six months of interim activity and a $3.5 million gross fundraise completed on July 1. The company announced an Early Access Program for eRapa and approval to expand the Serenta trial into Canada during the period. The unaudited interim results were dated September 11, 2026. Biodexa said the financing outlook carries potential dilution, while its directors continue evaluating available funding options.

Clinical Programs Expand

After the reporting period, enrollment reached 92 subjects from a planned 168. Fiona Sharp became chief financial officer and company secretary and joined the Board of Directors from January 2026.

Financing Provides Additional Cash

The transaction generated gross proceeds of $3.5 million. The Balance Sheet showed cash and cash equivalents of £3.23 million at June 30. The directors said cash-flow forecasts covering the next three years, including the 12 months from approval of the interim financial information, require further financing during Q4 2026 under the stated operating assumptions. Biodexa has a $35 million Equity Line of Credit entered into in 2025. The company said there is no guarantee that it can use the ELOC or raise other financing as needed for operations.

Funding Risks

The directors said financing conditions for small and micro-cap biotech companies remain challenging. They are evaluating financing alternatives, including Options connected with acquisitions and mergers, subject to agreement with counterparties. The directors said financing connected with potential alternatives could be dilutive. Further financing remains required during Q4 2026 based on the forecasts described in the interim financial information.